Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Contrast Clear all
Not listed Phase 2 Interventional

Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

NCT02018367
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Proflavine, high resolution imaging
Drug
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 25, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NCT04739800
View directory record Official record
Conditions
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
384
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed No phase listed Observational

Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age

NCT02609919
View directory record Official record
Conditions
Adverse Reaction to Drug, Allergic Reaction to Contrast Media
Interventions
Gadoteric Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 2 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

NCT07002450
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Flutter
Interventions
Cardiac computed tomography angiography, Standard of care management
Diagnostic Test · Other
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed No phase listed Observational

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
View directory record Official record
Conditions
Acute Kidney Injury, Contrast-induced Nephropathy
Interventions
RENISCHEM L-FABP POC Test
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Chandler, Arizona • Concord, California • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT04600115
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

NCT02752191
View directory record Official record
Conditions
Pediatric Congenital Heart Disease
Interventions
ferumoxytol, gadofosveset
Drug
Lead sponsor
Paul Finn
Other
Eligibility
1 Day to 6 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Phase 3 Interventional

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

NCT05470205
View directory record Official record
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of MRF for Characterization of Brain Tumors After Radiotherapy

NCT06101069
View directory record Official record
Conditions
Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Interventions
MRF in conjunction with IVIM MRI without contrast
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting No phase listed Observational

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

NCT06780241
View directory record Official record
Conditions
Aortic Regurgitation, Mitral Regurgitation, Aortic Stenosis
Interventions
CMR, Quality of Life Questionnaire
Diagnostic Test · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis

NCT01795456
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis, Arteritis, Vasculitis, Aortitis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT05281731
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Sonobiopsy, Research blood, Cancer Personalized Profiling, Definity®
Device · Procedure · Genetic
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

NCT00410956
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 6:16 AM EDT
Not listed No phase listed Observational

Skeletal Muscle Perfusion With LVAD

NCT02105831
View directory record Official record
Conditions
Heart Failure
Interventions
Contrast ultrasound skeletal muscle perfusion imaging
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 25, 2026, 6:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

NCT05591053
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms, Esophageal Diseases, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagus SCC, Esophagus Tumor, Esophagus Adenocarcinoma, Esophagus Neoplasm
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Phase 4 Interventional

CEUS for Blunt Abdominal Trauma in Children

NCT03490929
View directory record Official record
Conditions
Trauma Abdomen
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 6:16 AM EDT
Terminated Not applicable Interventional

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

NCT02269111
View directory record Official record
Conditions
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
diffusion-weighted magnetic resonance imaging, chemical exchange saturation transfer magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, dynamic susceptibility contrast-enhanced magnetic resonance imaging
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Completed No phase listed Observational

Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow

NCT05305378
View directory record Official record
Conditions
Aneurysm, AVM, Dural Arteriovenous Fistula, Glioma, Meningioma, Metastasis, Bypass
Interventions
Laser speckle contrast imaging (LSCI)
Device
Lead sponsor
Dynamic Light
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block

NCT07174440
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine (Epidural analgesia), Dexmedetomidine, Iohexol, QST Procedure
Drug · Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Terminated Phase 4 Interventional Results available

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

NCT04625517
View directory record Official record
Conditions
Breast Cancer
Interventions
Digital Mammography, Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 25, 2026, 6:16 AM EDT
Terminated No phase listed Observational

CT for Pulmonary Thromboembolic Disease

NCT02241525
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

NCT00625365
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
DEFINITY®
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Newark, Delaware • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 25, 2026, 6:16 AM EDT